Acelyrin

ACELYRIN's Phase 2b/3 trial of izokibep for uveitis failed to meet primary and secondary endpoints, leading to no further investment in izokibep. The company will focus on lonigutamab for thyroid eye disease, with Phase 3 trials starting Q1 2025. ACELYRIN has sufficient funds to support operations until mid-2027.

ACELYRIN's Phase 2b/3 trial for izokibep in uveitis failed to meet primary and secondary endpoints, leading to no further investment in izokibep. The company shifts focus to lonigutamab for thyroid eye disease, with Phase 3 trials planned for Q1 2025. ACELYRIN's cash reserves are projected to fund operations until mid-2027.

Point72 Asset Management increased its stake in Acelyrin by 566.7% in Q3, owning 250,300 shares. Other hedge funds also adjusted holdings, with institutional investors owning 87.31% of Acelyrin. Analysts set varied price targets, with Acelyrin's stock trading down 11.6%. Acelyrin focuses on developing transformative medicines, with its lead product in Phase 3 trials.

ACELYRIN's Phase 2b/3 trial of izokibep for uveitis failed to meet primary and secondary endpoints, leading to no further investment in izokibep. The company shifts focus to lonigutamab for thyroid eye disease, with Phase 3 trials set for Q1 2025. ACELYRIN's financials support operations until mid-2027.

Eco Wave Power secures $3.0M for Portugal project. Next Level Aviation gets $50M credit. ConocoPhillips offers $4.04B for Marathon Oil's debt. Chevron expands refinery. Nutanix plans $750M notes. American Strategic sells property for $63.5M. AMD, Marvell, ACMR, Darling Ingredients, GameStop, Stitch Fix, MIND, ImmunityBio, Mawson, Eagle Materials, VICI, Summit Hotel, Geron, Cellectar, Incyte, Clene, ACELYRIN, Nextracker, Case IH, Travel + Leisure, Performant, Ouster announce updates.

ACELYRIN, INC. announced its Phase 2b/3 trial of izokibep for non-infectious, non-anterior uveitis failed to meet the primary endpoint, showing no significant improvement over placebo. Consequently, ACELYRIN will halt internal investment in izokibep, focusing instead on lonigutamab for thyroid eye disease. The trial showed a 45.0% treatment failure rate for izokibep vs. 50.7% for placebo, with no clinical benefit observed. ACELYRIN plans no operational changes, maintaining focus on lonigutamab development and projecting cash runway to mid-2027.

ACELYRIN announced its Phase 2b/3 trial of izokibep for non-infectious, non-anterior uveitis did not meet the primary endpoint. The company will not invest further in izokibep and will focus on lonigutamab for thyroid eye disease.

ACELYRIN, INC. announced Phase 2b/3 trial of izokibep for non-infectious, non-anterior uveitis did not meet primary endpoint, with 45.0% treatment failure rate vs. 50.7% for placebo (p-value: 0.4914). Despite favorable safety, no key secondary endpoints achieved significance. Izokibep shows promise in HS and PsA, contrasting with uveitis trial results.

ACELYRIN, INC. announced Phase 2b/3 trial of izokibep for uveitis did not meet primary or secondary endpoints. The company will focus on lonigutamab for thyroid eye disease, with Phase 3 trials starting Q1 2025. $562.4M in cash ensures funding through mid-2027 for trials and pipeline expansion.

ACELYRIN's Phase 2b/3 trial of izokibep for uveitis failed to meet primary and secondary endpoints, leading to no further investment in izokibep. The company shifts focus to lonigutamab for thyroid eye disease, planning a Phase 3 trial start in Q1 2025. With $562.4M in resources, ACELYRIN aims for pipeline expansion and milestones through mid-2027.